TIAA CREF Investment Management’s Forte Biosciences FBRX Stock Holding History

TIAA CREF Investment Management’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$330K	Sell	81 -45	-36%	-$174K	﹤0.01%	2749
2018 Q4	$388K	Buy	126 +6	+5%	+$25.8K	﹤0.01%	2673
2018 Q3	$700K	Buy	120 +36	+43%	+$137K	﹤0.01%	2584
2018 Q2	$294K	Sell	84 -14	-14%	-$51.3K	﹤0.01%	2948
2018 Q1	$436K	Buy	98 +2	+2%	+$9.26K	﹤0.01%	2800
2017 Q4	$369K	Buy	96 +35	+57%	+$140K	﹤0.01%	2893
2017 Q3	$283K	Hold	61	–	–	﹤0.01%	3006
2017 Q2	$273K	Buy	+61	New	+$343K	﹤0.01%	3052

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TIAA CREF Investment Management's FBRX Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Forte Biosciences (FBRX) stake by 36% in Q1 2019, selling an estimated $174K and leaving 81 shares worth $330K. The position accounts for ﹤0.01% of the portfolio, ranked #2749.

TIAA CREF Investment Management first reported a position in FBRX in Q2 2017 and has held it in 8 quarters since. The position peaked at $700K in Q3 2018. 78 funds tracked by Wall St. Rank hold FBRX as of Q1 2019.

TIAA CREF Investment Management held 81 shares of Forte Biosciences worth $330K as of Q1 2019.
TIAA CREF Investment Management sold 45 Forte Biosciences shares in Q1 2019, an estimated $174K.
Forte Biosciences made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2749 holding.
TIAA CREF Investment Management first reported a position in Forte Biosciences in Q2 2017 and has held it in 8 quarters since.
TIAA CREF Investment Management's Forte Biosciences position peaked at $700K in Q3 2018.
78 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.